127 related articles for article (PubMed ID: 38488343)
1. TRACK_9: Testosterone replacement assessment: Classical vs. functional hypogonadism‐knowledge from a 9‐year study.
Zitzmann M; Cremers JF; Krallmann C; Soave A; Kliesch S
Andrology; 2024 Mar; ():. PubMed ID: 38488343
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data.
Alwani M; Yassin A; Talib R; Al-Qudimat A; Aboumarzouk O; Al-Zoubi RM; Saad F; Haider KS; Al Ansari A
Vasc Health Risk Manag; 2021; 17():497-508. PubMed ID: 34465997
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study.
Saad F; Doros G; Haider KS; Haider A
Int J Obes (Lond); 2020 Jun; 44(6):1264-1278. PubMed ID: 32060355
[TBL] [Abstract][Full Text] [Related]
4. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
Zitzmann M; Cremers JF; Krallmann C; Kliesch S
Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
[TBL] [Abstract][Full Text] [Related]
5. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
[TBL] [Abstract][Full Text] [Related]
6. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
7. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study.
Haider KS; Haider A; Doros G; Traish A
J Urol; 2018 Jan; 199(1):257-265. PubMed ID: 28728990
[TBL] [Abstract][Full Text] [Related]
9. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial).
Groti Antonič K; Antonič B; Žuran I; Pfeifer M
Aging Male; 2020 Dec; 23(5):1442-1454. PubMed ID: 32844712
[TBL] [Abstract][Full Text] [Related]
10. Testosterone treatment and change of categories of the International prostate symptom score (IPSS) in hypogonadal patients: 12 years prospective controlled registry study.
Yassin A; Kelly D; Nettleship J; Talib R; Al-Zoubi RM; Aboumarzouk OM; Albaba B
Aging Male; 2023 Dec; 26(1):2220567. PubMed ID: 37287273
[TBL] [Abstract][Full Text] [Related]
11. Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size.
Yassin A; Alwani M; Al-Zoubi RM; Aboumarzouk OM; Talib R; Nettleship J; Kelly D; Albaba B
Int Urol Nephrol; 2023 Jul; 55(7):1649-1658. PubMed ID: 37148486
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups.
Traish AM; Haider A; Haider KS; Doros G; Saad F
J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):414-433. PubMed ID: 28421834
[TBL] [Abstract][Full Text] [Related]
13. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study.
Haider A; Saad F; Doros G; Gooren L
Obes Res Clin Pract; 2014; 8(4):e339-49. PubMed ID: 25091355
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
Corona G; Rastrelli G; Morgentaler A; Sforza A; Mannucci E; Maggi M
Eur Urol; 2017 Dec; 72(6):1000-1011. PubMed ID: 28434676
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies.
Saad F; Yassin A; Doros G; Haider A
Int J Obes (Lond); 2016 Jan; 40(1):162-70. PubMed ID: 26219417
[TBL] [Abstract][Full Text] [Related]
17. Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms.
Saad F; Doros G; Haider KS; Haider A
Investig Clin Urol; 2018 Nov; 59(6):399-409. PubMed ID: 30402573
[TBL] [Abstract][Full Text] [Related]
18. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss.
Yassin A; Doros G
Clin Obes; 2013 Jun; 3(3-4):73-83. PubMed ID: 24163704
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
Saad F; Caliber M; Doros G; Haider KS; Haider A
Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
[No Abstract] [Full Text] [Related]
20. The effects of long-term testosterone treatment on endocrine parameters in hypogonadal men: 12-year data from a prospective controlled registry study.
Yassin A; Saad F; Alwani M; Aboumarzouk OM; Al-Zoubi RM; Nettleship J; Kelly D; Al-Ansari A
Aging Male; 2022 Dec; 25(1):185-191. PubMed ID: 35903984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
